These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31383250)

  • 21. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice.
    Oshiro T; Shiotani A; Shibasaki Y; Sasaki T
    Anat Rec; 2002 Apr; 266(4):218-25. PubMed ID: 11920384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of osteoprotegerin expression by prostaglandin E2 is crucially involved in lipopolysaccharide-induced osteoclast formation.
    Suda K; Udagawa N; Sato N; Takami M; Itoh K; Woo JT; Takahashi N; Nagai K
    J Immunol; 2004 Feb; 172(4):2504-10. PubMed ID: 14764723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD44 Can Compensate for IgSF11 Deficiency by Associating with the Scaffold Protein PSD-95 during Osteoclast Differentiation.
    Kim H; Takegahara N; Walsh MC; Choi Y
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32290171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival.
    Okamatsu Y; Kim D; Battaglino R; Sasaki H; Späte U; Stashenko P
    J Immunol; 2004 Aug; 173(3):2084-90. PubMed ID: 15265944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro.
    Spencer GJ; Utting JC; Etheridge SL; Arnett TR; Genever PG
    J Cell Sci; 2006 Apr; 119(Pt 7):1283-96. PubMed ID: 16522681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1 alpha, and TNF-alpha through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.
    Yang S; Takahashi N; Yamashita T; Sato N; Takahashi M; Mogi M; Uematsu T; Kobayashi Y; Nakamichi Y; Takeda K; Akira S; Takada H; Udagawa N; Furusawa K
    J Immunol; 2005 Aug; 175(3):1956-64. PubMed ID: 16034140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro.
    Gartland A; Buckley KA; Bowler WB; Gallagher JA
    Calcif Tissue Int; 2003 Oct; 73(4):361-9. PubMed ID: 12874700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
    Nagata N; Kitaura H; Yoshida N; Nakayama K
    Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms involved in bone resorption.
    Udagawa N
    Biogerontology; 2002; 3(1-2):79-83. PubMed ID: 12014848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
    Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
    J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
    Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
    J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipopolysaccharide-induced osteoclastogenesis in Src homology 2-domain phosphatase-1-deficient viable motheaten mice.
    Hayashi S; Tsuneto M; Yamada T; Nose M; Yoshino M; Shultz LD; Yamazaki H
    Endocrinology; 2004 Jun; 145(6):2721-9. PubMed ID: 14988381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
    Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH
    Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serotonin regulates osteoclast differentiation through its transporter.
    Battaglino R; Fu J; Späte U; Ersoy U; Joe M; Sedaghat L; Stashenko P
    J Bone Miner Res; 2004 Sep; 19(9):1420-31. PubMed ID: 15312242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.